Fosun Kite
Annie Li has extensive experience in communications and public relations. Annie worked as an Associate Director of Communications & Public Relations at Fosun Kite from October 2018 to present. Prior to that, they worked as a Communications Manager at AstraZeneca from April 2018 to August 2018. Annie also held various roles at GSK, including Internal Communications & Engagement Manager from June 2015 to February 2018 and June 2014 to May 2015, and Communication Specialist from September 2010 to May 2014.
Annie Li completed their Bachelor of Arts (BA) degree in English Language and Literature, General at Anhui University from 2000 to 2004. Annie then pursued a Master of Arts (MA) degree in American Study at East China Normal University from 2004 to 2007.
This person is not in any teams
Fosun Kite
About Fosun Kite Biotechnology Co., Ltd. As a joint venture of Shanghai Fosun Pharmaceutical (Group) Co., Ltd and U.S. Kite Pharma, Fosun Kite Biotechnology Co., Ltd. (hereinafter referred as "Fosun Kite") was established in April 2017 in Shanghai China. Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients. In early 2017, Fosun Kite brought in the world’s first approved CAR-T therapy for NHL Axicabtagene ciloleucel (US trade name Yescarta) from Kite Pharma (project name FKC876). Having obtained the comprehensive technology transfer and commercial license, the company has built a class B+A clean cell preparation base which is up to the latest GMP standards and in line with Kite’s commercial production standards and plant design concept. In August 2018, FKC876 officially obtained the Investigational New Drug (IND) approval from China National Medical Products Administration (NMPA), and now is carrying out registrational clinical trials strictly following GCP and other regulatory requirements in China to provide evidence in support of its successful registration. In January 2019, a commercial manufacture base of approx.10,000sqm settled in South Zhangjiang for commercial production of CAR-T therapies including FKC876 following registration. Besides Yescarta, Fosun Kite also collaborates with leading immunotherapy R&D organizations at home and abroad to build a rich and independent R&D pipeline.